Subscribe to our newsletter to receive the latest product updates and special offers

Order by Signal Tickers
Filters
Overview Valuation Financial Ownership Performance Technical ETF ETF Perf Custom Charts Tickers Basic TA News Snapshot Maps Stats
#31 / 200 Total
VRPX - Virpax Pharmaceuticals Inc - Stock Price Chart
TickerVRPX [NASD]
CompanyVirpax Pharmaceuticals Inc
CountryUSA
IndustryBiotechnology
Market Cap1.56MEPS (ttm)-14.42
P/E-EPS this Y56.21%
Forward P/E-EPS next Y60.04%
PEG-EPS past 5Y-20.69%
P/S-EPS next 5Y-
P/B-EPS Q/Q-111.83%
Dividend-Sales Q/Q-
Insider Own10.99%Inst Own0.07%
Insider Trans0.00%Inst Trans-8.75%
Short Float2.32%EarningsMay 13/a
Analyst Recom1.00Target Price20.00
Avg Volume143.92K52W Range0.63 - 11.77
Virpax Pharmaceuticals, Inc. is a preclinical stage biopharmaceutical company, which engages in the development of branded, non-addictive pain management products. Its products include metered-dose spray, liposomal gel encapsulates, and intranasal spray. The company was founded by Anthony P. Mack and Jeffrey A. Gudin in 2016 and and is headquartered in Berwyn, PA.
ASLN - ASLAN Pharmaceuticals Ltd ADR - Stock Price Chart
TickerASLN [NASD]
CompanyASLAN Pharmaceuticals Ltd ADR
CountrySingapore
IndustryBiotechnology
Market Cap7.06MEPS (ttm)-1.99
P/E-EPS this Y36.62%
Forward P/E-EPS next Y-37.83%
PEG-EPS past 5Y17.51%
P/S0.59EPS next 5Y-
P/B-EPS Q/Q58.79%
Dividend-Sales Q/Q-
Insider Own3.48%Inst Own13.11%
Insider Trans0.00%Inst Trans-16.17%
Short Float1.36%EarningsMay 09/b
Analyst Recom1.00Target Price9.50
Avg Volume487.19K52W Range0.34 - 4.23
Jun-14-24 04:54PM ASLAN Pharmaceuticals Announces Plan to Implement ADS Ratio Change (GlobeNewswire) -12.17%
Jun-04-24 12:00PM All You Need to Know About ASLAN Pharmaceuticals (ASLN) Rating Upgrade to Buy (Zacks)
09:55AM Here's Why ASLAN Pharmaceuticals (ASLN) Could be Great Choice for a Bottom Fisher (Zacks)
May-21-24 07:00AM ASLAN Pharmaceuticals Presents Late-Breaking Translational Data on Eblasakimab in COPD at the American Thoracic Society International Conference (GlobeNewswire)
May-09-24 01:55PM ASLN Stock Earnings: ASLAN Pharma Beats EPS for Q1 2024 (InvestorPlace)
07:00AM ASLAN Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
May-07-24 07:30AM ASLAN Pharmaceuticals to Present Additional Data From Interim Analysis of TREK-DX Phase 2 Study of Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients During Virtual KOL Event (GlobeNewswire)
May-02-24 09:00AM ASLAN Pharmaceuticals Announces Expansion of its Collaboration With Zenyaku to Investigate the Biology Underlying Differential Effects of Eblasakimab Compared to Other Biologics (GlobeNewswire)
Apr-30-24 07:00AM ASLAN Pharmaceuticals to Host KOL Panel Discussion on Treatment Options for Atopic Dermatitis Patients With an Inadequate Response to Dupilumab (GlobeNewswire)
Apr-24-24 07:00AM ASLAN Pharmaceuticals Announces Late Breaking Abstract on Eblasakimab in COPD Accepted for Presentation at the American Thoracic Society International Conference (GlobeNewswire)
Aslan Pharmaceuticals Ltd. is a clinical-stage immunology biopharmaceutical company, which develops novel therapeutics. It focuses on atopic dermatitis, other immunology indications and autoimmune disease. Its pipeline includes ASLAN003 and Eblasakimab. The company was founded by Carl Aslan Jason Morton Firth, Mark McHale, and Jeffrey Tomlinson in 2010 and is headquartered in Singapore.
MGX - Metagenomi Inc. - Stock Price Chart
TickerMGX [NASD]
CompanyMetagenomi Inc.
CountryUSA
IndustryBiotechnology
Market Cap145.34MEPS (ttm)-
P/E-EPS this Y83.80%
Forward P/E-EPS next Y1.98%
PEG-EPS past 5Y-
P/S-EPS next 5Y-
P/B0.53EPS Q/Q-329.49%
Dividend-Sales Q/Q127.13%
Insider Own50.36%Inst Own28.37%
Insider Trans5.01%Inst Trans-
Short Float0.36%EarningsMay 14/a
Analyst Recom1.29Target Price16.83
Avg Volume99.18K52W Range4.20 - 12.74
Metagenomi, Inc. is a precision genetic medicines company, which engages in the business of developing next generation gene-editing technologies and therapies. Its business activities include developing gene edit-ing toolbox, ther-a-peu-tic focus, and processing discovery platform. The company was founded by Brian C. Thomas on September 16, 2016 and is headquartered in Emeryville, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Novo Holdings A/S10% OwnerFeb 13 '24Buy15.00800,00012,000,0001,739,175Feb 15 08:38 PM
Novo Holdings A/S10% OwnerFeb 09 '24Buy10.25100,0001,025,000100,000Feb 15 08:38 PM
UBX - Unity Biotechnology Inc - Stock Price Chart
TickerUBX [NASD]
CompanyUnity Biotechnology Inc
CountryUSA
IndustryBiotechnology
Market Cap21.83MEPS (ttm)-2.51
P/E-EPS this Y32.37%
Forward P/E-EPS next Y-9.11%
PEG-EPS past 5Y36.93%
P/S-EPS next 5Y-
P/B0.91EPS Q/Q54.55%
Dividend-Sales Q/Q-
Insider Own8.57%Inst Own14.28%
Insider Trans-0.17%Inst Trans117.91%
Short Float2.17%EarningsMay 14/a
Analyst Recom1.00Target Price6.67
Avg Volume60.01K52W Range1.38 - 3.48
Unity Biotechnology, Inc. operates as a biotechnology company. The firm is developing a portfolio of programs like biological mechanisms implicated in diseases of aging, and also senolytic programs in ophthalmologic and neurologic disorders. The company was founded by Nathaniel Eames David, Jan van Deursen, Judith Campisi, and Daohong Zhou on March 30, 2009 and is headquartered in South San Francisco, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Ghosh AnirvanChief Executive OfficerMay 02 '24Sale1.5560393578,143May 03 04:05 PM
Ghosh AnirvanChief Executive OfficerFeb 02 '24Sale1.716801,16378,746Feb 05 04:05 PM
Ghosh AnirvanChief Executive OfficerJan 30 '24Sale1.711,1832,02379,426Jan 31 04:05 PM
Ghosh AnirvanChief Executive OfficerNov 02 '23Sale1.835891,07880,609Nov 03 04:05 PM
Ghosh AnirvanChief Executive OfficerOct 30 '23Sale1.901,0241,94681,198Oct 31 04:05 PM
IDAI - T Stamp Inc - Stock Price Chart
TickerIDAI [NASD]
CompanyT Stamp Inc
CountryUSA
IndustrySoftware - Application
Market Cap5.51MEPS (ttm)-0.91
P/E-EPS this Y33.64%
Forward P/E-EPS next Y46.48%
PEG-EPS past 5Y-51.27%
P/S1.18EPS next 5Y-
P/B3.80EPS Q/Q47.54%
Dividend-Sales Q/Q25.08%
Insider Own17.56%Inst Own1.84%
Insider Trans0.00%Inst Trans-
Short Float1.78%EarningsMay 14/b
Analyst Recom1.00Target Price2.00
Avg Volume263.53K52W Range0.50 - 3.50
T Stamp, Inc. engages in the provision of identity verification services to facilitate Internet-mediated economic and social transactions. It guards against identity theft and friendly-fraud by providing a secure digital token verifying the user's photograph, identity and trustworthiness. The company was founded by Gareth Genner, Andrew Gowasack, Catherine Lambert and Mike Lindenau in 2015 and is headquartered in Atlanta, GA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Gowasack Andrew CarlPresidentMay 16 '24Option Exercise0.0055,7190314,527May 20 10:16 AM
Allen JoshuaExecutive Vice PresidentMay 16 '24Option Exercise0.009,648020,989May 20 10:33 AM
Valdes AlexanderChief Financial OfficerMay 16 '24Option Exercise0.0041,4440120,075May 20 10:41 AM
McClintock WilliamDirectorMay 16 '24Option Exercise0.0018,504041,472May 20 11:07 AM
Genner Gareth NevilleChief Executive OfficerMay 16 '24Option Exercise0.0068,8560240,657May 20 11:37 AM
CRT - Cross Timbers Royalty Trust - Stock Price Chart
TickerCRT [NYSE]
CompanyCross Timbers Royalty Trust
CountryUSA
IndustryOil & Gas E&P
Market Cap68.34MEPS (ttm)1.57
P/E7.27EPS this Y-1.70%
Forward P/E-EPS next Y-
PEG-EPS past 5Y6.20%
P/S6.63EPS next 5Y-
P/B25.89EPS Q/Q-59.00%
Dividend11.69%Sales Q/Q-51.30%
Insider Own1.00%Inst Own8.80%
Insider Trans0.00%Inst Trans-8.33%
Short Float0.23%Earnings-
Analyst Recom-Target Price-
Avg Volume42.88K52W Range12.45 - 24.44
Cross Timbers Royalty Trust operates as an express trust in the United States. It holds 90% net profits interests in certain producing and nonproducing royalty and overriding royalty interest properties in Texas, Oklahoma, and New Mexico; and 75% net profits working interest in four properties in Texas and three properties in Oklahoma. The company was founded in 1991 and is based in Dallas, Texas.
CERO - CERo Therapeutics Holdings Inc. - Stock Price Chart
TickerCERO [NASD]
CompanyCERo Therapeutics Holdings Inc.
CountryUSA
IndustryBiotechnology
Market Cap4.73MEPS (ttm)-0.46
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y-
P/S-EPS next 5Y-
P/B-EPS Q/Q-119.66%
Dividend-Sales Q/Q-
Insider Own53.66%Inst Own0.47%
Insider Trans0.00%Inst Trans6.12%
Short Float1.65%Earnings-
Analyst Recom-Target Price-
Avg Volume1.17M52W Range0.33 - 12.80
CERo Therapeutics Holdings, Inc. is a blank check company, formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. The company was founded on June 8, 2021 and is headquartered in Oakland, CA.
ADVM - Adverum Biotechnologies Inc - Stock Price Chart
TickerADVM [NASD]
CompanyAdverum Biotechnologies Inc
CountryUSA
IndustryBiotechnology
Market Cap136.81MEPS (ttm)-10.23
P/E-EPS this Y47.32%
Forward P/E-EPS next Y6.97%
PEG-EPS past 5Y0.36%
P/S-EPS next 5Y-
P/B0.75EPS Q/Q48.07%
Dividend-Sales Q/Q-100.00%
Insider Own37.22%Inst Own45.84%
Insider Trans3.07%Inst Trans2.89%
Short Float5.87%EarningsMay 09/a
Analyst Recom1.29Target Price35.33
Avg Volume306.93K52W Range7.24 - 29.70
Adverum Biotechnologies, Inc. is a clinical-stage gene therapy company that engages in the development of gene therapies for ocular and rare diseases. The company was founded by Mark S. Blumenkranz, Thomas W. Chalberg, Jr., Mitchell H. Finer, and Steven Daniel Schwartz on July 17, 2006 and is headquartered in Redwood City, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Lupher, Jr. Mark L.DirectorFeb 07 '24Buy1.35130,000175,500130,000Feb 09 05:50 PM
Scopa James PaulDirectorFeb 07 '24Buy1.35100,000135,000100,000Feb 09 05:51 PM
Seyedkazemi SetarehChief Development OfficerSep 15 '23Sale1.526,2019,42947,674Sep 18 06:54 PM
MYNZ - Mainz Biomed N.V. - Stock Price Chart
TickerMYNZ [NASD]
CompanyMainz Biomed N.V.
CountryGermany
IndustryDiagnostics & Research
Market Cap12.59MEPS (ttm)-1.64
P/E-EPS this Y50.82%
Forward P/E-EPS next Y20.29%
PEG-EPS past 5Y-
P/S13.99EPS next 5Y-
P/B3.75EPS Q/Q-1124.50%
Dividend-Sales Q/Q-
Insider Own21.63%Inst Own0.67%
Insider Trans0.00%Inst Trans-2.23%
Short Float2.48%EarningsApr 09/b
Analyst Recom1.67Target Price3.00
Avg Volume170.22K52W Range0.55 - 5.01
Mainz Biomed NV is a molecular genetics cancer diagnostic company. The firm is engaged in the developing of market-ready molecular genetic diagnostic solutions for life-threatening conditions. It is involved in the commercializing of its product portfolio in Europe, the United States, and the rest of world. The company was founded on March 08, 2021 and is headquartered in Mainz, Germany.
AKTS - Akoustis Technologies Inc - Stock Price Chart
TickerAKTS [NASD, RUT]
CompanyAkoustis Technologies Inc
CountryUSA
IndustryCommunication Equipment
Market Cap13.28MEPS (ttm)-1.00
P/E-EPS this Y19.60%
Forward P/E-EPS next Y41.34%
PEG-EPS past 5Y0.80%
P/S0.44EPS next 5Y-
P/B0.29EPS Q/Q-11.97%
Dividend-Sales Q/Q2.09%
Insider Own4.96%Inst Own37.34%
Insider Trans38.22%Inst Trans-1.99%
Short Float9.97%EarningsMay 13/b
Analyst Recom2.50Target Price0.75
Avg Volume11.78M52W Range0.12 - 3.36
Akoustis Technologies, Inc. is a filter solutions company, which engages in the development, design, and manufacture of radio frequency (RF) filter products. It operates through the Foundry Fabrication Services and RF Filters segments. The Foundry Fabrication Services segment is composed of engineering review services and STC-MEMS foundry services. The RF Filters segment includes amplifier and filter product sales, and grant revenue. The company was founded by Jeffrey B. Shealy in 2014 and is headquartered in Huntersville, NC.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Shealy Jeffrey B.Chief Executive OfficerJan 29 '24Buy0.501,310,000655,0002,222,775Jan 31 06:39 PM
Aichele DavidEVP of Business DevelopmentJan 29 '24Buy0.5080,00040,000334,622Jan 31 06:39 PM
Boller KennethCFOJan 29 '24Buy0.5060,00030,000214,957Jan 31 06:39 PM
Geiss ArthurDirectorJan 29 '24Buy0.5050,00025,000415,924Jan 31 06:40 PM
Aichele DavidEVP of Business DevelopmentDec 18 '23Sale0.721,5001,083254,622Dec 20 05:03 PM
1234567891020